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It is becoming increasingly clear that short and long noncoding RNAs critically participate in the regulation of cell growth,
differentiation, and (mis)function. However, while the functional characterization of short non-coding RNAs has been reaching
maturity, there is still a paucity of well characterized long noncoding RNAs, even though large studies in recent years are rapidly
increasing the number of annotated ones. The long noncoding RNA PVT1 is encoded by a gene that has been long known since it
resides in the well-known cancer risk region 8q24. However, a couple of accidental concurrent conditions have slowed down the
study of this gene, that is, a preconception on the primacy of the protein-coding over noncoding RNAs and the prevalent interest in
its neighbor MYC oncogene. Recent studies have brought PVT1 under the spotlight suggesting interesting models of functioning,
such as competing endogenous RNA activity and regulation of protein stability of important oncogenes, primarily of the MYC
oncogene. Despite some advancements in modelling the PVT1 role in cancer, there are many questions that remain unanswered
concerning the precise molecular mechanisms underlying its functioning.
1. Introduction
Evidence strongly supports pervasive transcription of human
genomes, even though only 2% of transcripts encode proteins
[1–5]. Noncoding transcripts were for long time regarded
as evolutionary junk or transcriptional noise, but, with the
development ofwhole genome technologies, these noncoding
RNAs (ncRNAs) are emerging as important regulators of gene
expression.This variegated class of RNA species encompasses
the well-known microRNAs (miRNAs), as well as the most
recently acknowledged long noncoding RNAs (lncRNAs).
Noncoding transcripts are usually classified on the basis
of their size [6]: miRNAs are single-stranded short RNAs
(∼22 nucleotides long) that posttranscriptionally regulate
gene expression by translation inhibition or degradation of
their target mRNAs [7–10]; long noncoding RNAs (lncRNAs)
are broadly categorized as RNA longer than 200 nucleotides
lacking extended open reading frames [11].
While miRNAs have been extensively studied [7–10],
lncRNAs still constitute a new, potentially fascinating, terri-
tory yet to be explored. Recent studies have begun to associate
subsets of lncRNAs to specific regulatory mechanisms [6, 12–
16] of important biological processes, including cell prolif-
eration, survival, differentiation, and chromatin remodelling
both in cis and in trans. Many functional lncRNAs have been
shown to play key roles in organ development and cancer;
however the biological functions of the majority of lncRNAs
largely remain to be identified. Increasing experimental
evidence supports the hypothesis that lncRNAs may possess
competing endogenous RNA (ceRNA) activity [6, 17–21].
This intriguing mechanism concerns the ability of some
RNAs to compete for miRNA binding.
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Our group recently developed a computational model
able to identify putative ceRNAs among lncRNAs [21] and
used it to build normal and cancer networks of miRNA-
mediated sponge interactions (MMI-networks). The above
ceRNA model, which we applied to breast cancer data from
the Cancer Genome Atlas (TCGA) [22], allows characteriza-
tion of lncRNAs in terms of oncogenes or tumor-suppressors
protagonists in cancer. This speculation was gleaned by the
observation of a marked rewiring in the ceRNA program
between normal and pathological breast tissues. Most impor-
tantly, this analysis fueled our interest in the lncRNA PVT1 as
being the first hub of the normal-MMI-network. We found
that PVT1 favors binding to the crucial mir-200 family as
the bone of contention with plenty of competitor mRNAs
with declared importance in tumorigenesis since this miRNA
family mediates over 80% of the interactions included in the
PVT1 MMI-subnetwork in normal breast.
The human PVT1 gene (also known as Pvt1 oncogene) is
a long intergenic noncoding RNA (lincRNA) homologous to
the mouse plasmacytoma variant translocation gene (Pvt1).
Indeed this locus has been first discovered in the mid 80s
in mouse as frequently involved in a variant translocation
in plasmacytomas [23, 24]. Shortly after, the PVT1 locus
emerged as a site of variant translocations also in human
Burkitt’s lymphomas [25–27]. Around the same years, sys-
tematic studies conducted in mice and rats to find common
retroviral integration sites in T lymphomas revealed the Pvt1
gene as one such locus, suggesting its oncogenic potency
[28–30]. This oncogenic attitude of PVT1 gained support
from later evidences of frequent upregulation [21, 31–35] and
amplification in a wide variety of cancers. Moreover, PVT1
lies in a recognized cancer risk locus that it shares with
the well-known MYC oncogene. This site, which maps to
chromosome 8 in human, is among the top target of copy
number alterations in cancer and has equivalents in both
mouse (chromosome 15) and rat (chromosome 7) [25, 28, 36,
37].
In the light of all the above, we can hazard a guess that
if PVT1 was a protein-coding gene it would have been at
the heart of countless studies aimed at the functional char-
acterization since its discovery. Rather, being a noncoding
transcript has slowed the process of shading light on its
mechanisms of action, for reasons of both technical and
cultural nature. In the early years of its discovery, in fact, on
the one hand the classicalmolecular techniques for functional
investigation were not suited to detecting and analyzing
noncodingRNAs; on the other hand it was hardly conceivable
that what was still deemed as transcriptional noise could play
an active role in the regulation of important processes.
Instead, the technological revolution of recent years along
with the unprecedented appreciation of the multifaceted
world of noncoding RNAs has led to a renewed interest in
the investigation of the PVT1 function. This growing interest
is reflected in the multitude of papers published in the last
few years on PVT1 (Figure 1). As a consequence, new inter-
esting hypotheses are emerging on the regulatory networks
involving PVT1 in normal cells and disease. Nonetheless, the
precise mechanism of PVT1 functioning still remains largely
unknown.
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Figure 1: Rising interest in the oncogenic lncRNA PVT1. Barplot
showing the frequency for publications having the word “PVT1”
in the title and/or abstract listed in PubMed http://www.ncbi
.nlm.nih.gov/pubmed, as of January 2015.
2. PVT1 Genomic Locus
In humans the chromosomal locus encoding PVT1
(Figure 2(a)) maps to band 4 of region 2 on the long arm
of chromosome 8 (8q24), specifically to sub-subband 1 of
subband 2 therein (8q24.21). The 8q24 locus has often
attracted the attention of researchers for at least three main
reasons: (i) it constitutes a preferred site for genetic aberra-
tions, including translocation [25, 37, 38], amplification
[25, 38–41], and viral integration [42, 43] in a wide variety
of cancers and other malignancies (Figure 2(b)); (ii) it
encompasses multiple risk loci for different diseases [44–56];
and (iii) it includes a 1.8-megabases region of gene desert,
so termed due to paucity of transcriptional activity [57, 58],
which is considered a cancer risk site likely involved in
long-range interactions that affect the expression of distant
genes [45, 59, 60]. Indeed, chromosome conformation
capture- (3C-) based studies have confirmed extensive phys-
ical contacts of this risk locus with multiple genomic regions,
including intrachromosomal interactions with the PVT1
locus [60, 61].
Another remarkable feature of the PVT1 locus is to reside
some 60 kilobases (kb) 3-prime of the well-known MYC
oncogene and different functional interactions between these
two genes have been proposed [41, 62]. Adding to this, the
MYC-PVT1 pair of genes results syntenic in human (chromo-
some 8), mouse (chromosome 15), and rat (chromosome 7)
(Figure 2(c)) [25, 37]. Yet, there is also evidence for indepen-
dent contribution of PVT1 and MYC to disease [31, 60].
Both the mouse and the rat homologous of human PVT1
(Pvt1 and Mis-1, resp.) constitute sites of frequent retroviral
integration [59, 63–66] and, similarly to the human counter-
part, sites of frequent translocations in B-cell derived tumors
(i.e., Burkitts lymphoma, plasmacytoma, and immunocy-
toma in human, mouse, and rat, resp.) [23, 25, 67].
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Figure 2: The PVT1 locus in humans. (a) UCSC Genome Browser (http://genome.ucsc.edu/) view of the 8q24.21 region in humans, which
contains the PVT1 gene. (b) Barplot of cross cancer alteration frequency for the PVT1 gene. 𝑥-axis: different cancer types from the Cancer
Genome Atlas [22]. 𝑦-axis: total frequency of PVT1 gene alterations. Summary of TCGA cross cancer data and visualization obtained from
the cBioPortal for Cancer Genomics (http://www.cbioportal.org/). (c) Sketch of rat and mouse genomic regions syntenic to the human
MYC/PVT1 region.
3. PVT1 Expression in Normal
Tissues and in Disease
The PVT1 gene [68] spans across a genome interval of over
300 kb (i.e., bases 128806779–129113499 within the February
2009 human genome build GRCh37/hg19) on the forward
strand of chromosome 8. The high complexity of the gene
architecture of PVT1 has been long known [69] and most
recent studies based on high-throughput techniques for gene
expression analysis have confirmed it [21, 31, 41]. In fact, the
large PVT1 locus gives rise to over 20 different variants of the
lncRNA according to the Ensembl annotations of the human
genome (release 75) [70] (Figure 2(a)). Moreover, a landmark
study recently published by the FANTOM consortium [71]
that compiled a whole genome map of human and mouse
promoters by using cap analysis of gene expression (CAGE)
technique has annotated multiple transcription start sites
(TSS) overlapping the PVT1 locus.The same PVT1 locus also
produces a cluster of six annotatedmicroRNAs (namely,miR-
1204, miR-1205, miR-1206, miR-1207-5p, miR-1207-3p, and
miR-1208) [72]. The FANTOM study also provided the first
comprehensive atlas of gene expression across human body
and cell lines from which a global view of the expression
pattern of PVT1 can be derived (Figures 3(a)–3(c)). Genome-
wide expression studies in humans and other organisms
have reported that neighboring genes tend to have correlated
expression patterns [73–75]. Indeed, a comparison of the
expression levels of PVT1 versus its neighbor MYC gene
across the samples included in the above compendium of
gene expression data showed a statistically significant Pearson
correlation (𝑟 = 0.5 and 𝑃 values = 10−32, Figure 3(d)).
This coexpression could be indicative of a transcriptional
coregulation and of a possible involvement in common
functional pathways. Overall, the expression levels of PVT1
appear to be higher (up to 100 times) in cancer cell lines than
in human primary cells and tissues. This trend strengthens
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Figure 3:The PVT1 expression in a human atlas. (a–c) Barplots of sorted PVT1 expression values across human cell lines, tissues, and primary
cells, respectively. Expression data are taken from the atlas recently released by the FANTOM consortium [71]. 𝑦-axis: normalized expression
value (tags per million). 𝑥-axis: human cell lines, tissues, and primary cells, respectively. In each panel, the name of the top 20 samples is
listed and the corresponding bars are similarly colored. In (a), the inset shows the overall sorted PVT1 expression values in human cell lines.
The PVT1 expression data plotted in (a–c) (i.e., 186 cell lines, 113 tissues, and 136 primary cells) constitute a subset of the full FANTOM atlas
(>850 samples) that was selected to reduce redundancy in the plots. (d) Scatterplot of the MYC versus PVT1 expression values across all the
samples analyzed in (a–c). The Pearson correlation (𝑟) and the corresponding 𝑃 value are shown.
the experimental evidences of its overexpression in a wide
variety of tumors [31–35], with or without a concurrent copy
number amplification [31]. The increased expression in
tumors (Figures 4(a)-4(b)) and the high Pearson correlation
between PVT1 and MYC expression levels (Figure 4(c)) are
both fully recovered in an analysis of the large collection of
tumor expression data provided by TCGA project.
4. PVT1 Function
By analysing the breast cancer data set provided by TCGA,
we found [21] that PVT1 acts as ceRNA in the normal-MMI-
network but not in cancer (Figure 5(a)). Moreover, PVT1
revealed a net binding preference towards themir-200 family,
which it antagonizes to regulate the expression of hundreds
of mRNAs in the normal case. In fact in normal breast
we reported for PVT1 a subnetwork of ceRNA interactions
connecting it to 753 different mRNAs (i.e., 50% of total
mRNAs comprising the whole normal-MMI-network) and
surprisingly over 80% of these ceRNA interactions stood
from competition for binding with members of the same
miRNA family: the mir-200 family.
In terms of topological properties, PVT1 switches from
being the first of the hubs in the normal-MMI-network
to fall outside the list of nodes of the cancer network.
Interestingly, recent studies suggested a role for PVT1 in the
pathophysiology of breast cancer by virtue of PVT1-mediated
inhibition of apoptosis and increasing of proliferation, when
overexpressed [31].
Among competitors of PVT1 for binding to the mir-200
family in normal breast tissues, there are some important
regulators of breast tissue morphogenesis and development,
such as CDH1; all the three members of the extended p53
family (i.e., TP53, TP63, and TP73); two members of the
mammalian RUNX family (i.e., RUNX1 and RUNX3); and
GATA3. CDH1 (also known as E-cadherin) is a crucial
cell-cell adhesion molecule considered as an epithelial cell
marker. Loss of function of CDH1 has been associated with
increased proliferation, invasiveness, and/or metastasis in
several epithelial cancers, including breast cancer [76]. TP53
is the most extensively studied tumor suppressor and acts
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Figure 4: PVT1 expression in cancer. (a) Barplots of mean PVT1 expression in cancer versus normal tissues from the Cancer Genome
Atlas [22]. Values are ordered by decreasing abundance in cancer. 𝑦-axis: normalized expression value (FPKM). 𝑥-axis: TCGA tissues. (b)
Barplots ofmean PVT1 expression in TCGA cancer tissues, ordered by decreasing abundance. 𝑥-axis and 𝑦-axis: same as in (a). (c) Scatterplot
of the MYC versus PVT1 expression values across all the samples analyzed in (a-b). The Pearson correlation (𝑟) and the corresponding
𝑃 value are shown. Abbreviations: acc: adrenocortical carcinoma; blca: bladder urothelial carcinoma; lgg: brain lower grade glioma; brca:
breast invasive carcinoma; cesc: cervical squamous cell carcinoma and endocervical adenocarcinoma; chol: cholangiocarcinoma; coad: colon
adenocarcinoma; gbm: glioblastoma multiforme; hnsc: head and neck squamous cell carcinoma; kich: kidney chromophobe; kirc: kidney
renal clear cell carcinoma; kirp: kidney renal papillary cell carcinoma; lihc: liver hepatocellular carcinoma; luad: lung adenocarcinoma;
lusc: lung squamous cell carcinoma; dlbc: lymphoid neoplasm diffuse large B-cell lymphoma; meso: mesothelioma; ov: ovarian serous
cystadenocarcinoma; paad: pancreatic adenocarcinoma; pcpg: pheochromocytoma and paraganglioma; prad: prostate adenocarcinoma; read:
rectum adenocarcinoma; sarc: sarcoma; skcm: skin cutaneous melanoma; tgct: testicular germ cell tumors; thym: thymoma; thca: thyroid
carcinoma; ucs: uterine carcinosarcoma; ucec: uterine corpus endometrial carcinoma; uvm: uveal melanoma.
in response to diverse forms of cellular stresses to induce
cell cycle arrest, apoptosis, and senescence [77, 78]. The
two identified homologues, TP63 and TP73, have also been
related to apoptosis, and a possible role as tumor suppressors
has been suggested [77]. RUNX1 is the predominant RUNX
familymember expressed in human breast epithelial cells and
there is a growing body of evidence suggesting its possible
role as a breast cancer suppressor [79–82]. RUNX3 has
been recently reviewed as a tumor suppressor, specifically in
human breast cancer, with decreasing expression associated
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Figure 5: The PVT1 functions. (a) Model of PVT1 ceRNA mechanism operating in normal breast but not in breast cancer tissues possibly
due to a prevalence in cancer of expression of PVT1 isoforms lacking recognition elements for the miRNA to be sponged, as it has been
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with disease progression [80, 83]. Finally, GATA3 has been
linked to mammary gland morphogenesis, mammary tumor
differentiation, and metastasis [84].
Thus, the PVT1 neighborhood in the normal-MMI-net-
work encompasses cancer related genes as well as genes
involved in mammary gland development and cell mor-
phogenesis and the sponge program orchestrated by PVT1
results completely abolished in cancer. Taken together these
findings may be indicative of a possible PVT1 surveillance
role aimed to preserve cell-cell adhesion. Indeed, mammary
glandmorphogenesis results from the coordination of diverse
cellular processes involving cell-cell adhesion, migration,
proliferation, and apoptosis. Thus, PVT1 controlling circuit
may provide further insight in solving this complicated
puzzle.
The specific conditions required for ceRNA network to
occur are still far from being determined. The importance
of the relative concentration of the ceRNAs, as well as their
related miRNAs, has been recently emphasized [85]. Large
changes in the ceRNA expression levels either overcome
or relieve the miRNA repression on competing ceRNAs;
similarly, a very large miRNA overexpression may abolish
competition. However, both the mir-200 family members
and PVT1 appear highly upregulated in the breast cancer
dataset analysed in [21]. Thus, we formulated an alternative
hypothesis for the abolishment of the ceRNA activity of PVT1
in cancer, prompted by the existence of multiple isoforms
produced by its genomic locus. In fact, despite most of the
PVT1 alternative isoforms harboring seed matches for the
mir-200 family members, two isoforms lack the putative
binding sites for this miRNA family. Hence, the observed
withdrawal in cancer of the PVT1 sponge activity may be
due to the preferential expression of these two isoforms,
independently from the abundance of PVT1 (Figure 5(a)).
A completely different way of functioning of PVT1 comes
from new findings that highlight its involvement in the
regulation of the oncoprotein MYC [41]. According to this
study, PVT1 controls levels of MYC through regulation of
the protein stability and they both cooperate to promote cell
proliferation in cancer. In [41], the authors analyzed copy
number variation data from two large cancer databases (i.e.,
Progenetix and TCGA) and consistently observed (98% of
cases) a cogain of MYC and PVT1 across a wide variety of
cancers with amplified 8q24 region. This PVT1 and MYC
protein coamplification was confirmed in a panel of 8 human
primary tumors. Moreover, depletion of PVT1 by small
interference RNAs (siRNAs) caused the reduction of MYC
protein levels in a human colorectal cancer cell line and
nuclear colocalization of PVT1 and MYC was also shown. In
a breast cancer mouse model, Tseng and coworkers observed
a halving in the proliferation upon either MYC or PVT1
knockdown.Theobserved proliferative phenotype confirmed
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what was already reported in a previous study conducted in
ovarian and breast cancer cell lines [31]. Interestingly, while
the inhibition of either PVT1 or MYC affected proliferation,
a proapoptotic phenotype was exclusively observed when
silencing PVT1 [31]. All the above pieces of information were
reconciled by Tseng and coworkers in a unified model where
the lncRNA PVT1 interacts with MYC in the nucleus, either
directly or indirectly, and protects the MYC protein from
degradation by reducing phosphorylation of its threonine 58
residue (Figure 5(b)).
A recent screening for liver oncofetal (i.e., fetal specific
molecules misexpressed in cancer) lncRNAs in a mouse
model for hepatocellular carcinoma (HCC) supported the
role for PVT1 in regulating proliferation and the same pheno-
typewas confirmed in humanHCC cell lines [35]. In linewith
previous reports in other epithelial cancers [31, 32, 34, 35],
PVT1 was found to be upregulated in cancer compared to
noncancerous tissues and this upregulation was associated
with a worse prognosis in a panel of HCC patients. Moreover,
the authors found that the upregulated PVT1 induces cell
cycle genes and activation of the TGF𝛽1 signaling pathway
(Figure 5(c)) and suggested a possible feedback loop between
this lincRNA and TGF𝛽1 [35]. Interestingly, the same authors
found that PVT1 interacts with the proliferation-associated
nucleolar protein NOP2 and stabilizes it from degradation
[35]. Remarkably, this model of functional interaction is
similar to that proposed between PVT1 and MYC [41].
5. Conclusions
A wide range of solid tumors often carry amplification of
the 8q24 locus, a large genomic region spanning the PVT1
gene and its bulky neighboring MYC. Despite early recog-
nition of the importance of this locus with respect to many
malignancies, the well-knownMYC oncogene has repeatedly
been considered the first guilt by association. While the role
of MYC in cancer has been proved beyond any doubt, the
presence of this famous neighbor together with the enigmatic
noncoding nature of PVT1 has hampered prompt recognition
that another important oncogene coexisted with MYC in
the 8q24 risk region. Nowadays, the accumulating evidences
showing that PVT1 and MYC have separate and distinct
oncogenic potential [21, 31, 32, 86] caused PVT1 to acquire
independent individuality with respect to MYC.
In conclusion, the foregoing considerations suggest to
think that the time has come for a thorough investigation of
the role played by PVT1 in tumors, a challenge full of promise.
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